Cancer Risk Scores: How Genes and Lifestyle Combine to Guide Prevention

Genetic studies have shown that a person’s DNA can hint at their chance of developing cancer. Scientists now mix this genetic signal with information about a person’s environment and habits to create a single score that predicts risk. The idea is that both inherited genes and everyday exposures—like diet, pollution, or stress—work together to influence cancer risk over a lifetime. These mixed scores are called composite risk scores, or CRS. They aim to help doctors spot people who might benefit from extra screening or lifestyle changes before a cancer develops. However, the evidence behind them comes from many different types of studies, each with its own strengths and limits. When researchers look at many cancers—breast, prostate, colorectal, and more—they find that people with higher CRS values generally have a higher chance of getting cancer. The jump in risk is steady as the score climbs, but the improvement in predicting who will actually develop cancer (measured by statistics like the area under the curve) is usually small. How well the scores work can vary a lot between different groups of people and in different health care settings.A major challenge is that most CRS tests have not been tried in diverse populations or in real‑world clinical practice. Problems such as overfitting (when a model works well on one dataset but not elsewhere), differences in ancestry, and how the scores are applied across different groups often go unreported. Because of these gaps, experts suggest that CRS should mainly be used to group people by risk level and to design studies that test prevention strategies, rather than as a tool for making individual treatment decisions. The most immediate benefit could be in targeting screening programs—like deciding who gets a colonoscopy or mammogram sooner than usual. To move CRS from research to everyday use, scientists need larger and more varied data sets, clear guidelines on how to apply the scores fairly, and rigorous tests that confirm they work across different populations. Only then can CRS become a reliable part of cancer prevention plans.